When hVIVO began working with respiratory syncytial virus (RSV), it was not a well-understood disease. We defined and calibrated a disease model that has now become the gold standard. Two different landmark studies conducted by hVIVO with Alios and Gilead for RSV therapies were both published in the highly respected New England Journal of Medicine. Given this success, we are using the same approach to develop new models for respiratory diseases, starting with asthma.
Asthma is a complex disease that affects more than 300 million people worldwide and, like flu and colds, asthma has no effective cure. It is comprised of subgroups with differing characteristics and potentially different therapeutic demands.
During 2015, hVIVO achieved a significant milestone with the official release of our human model of viral-induced asthma exacerbation. As we did with RSV, we first ran initial “calibration” studies to develop the model’s product specifications (i.e. endpoints, recruitment rates, trial design) to ready the model for release. In 2016, we have been conducting ground-breaking research in moderate to severe asthma patients, collecting and analysing samples to define asthma patient subtypes and identify disease mechanisms. These results will provide hVIVO, for the first time, the ability to stratify patients and benchmark targeted therapies – eliminating the mass numbers and uncertainties inherent in today’s asthma trials.
The second half of 2016 saw us kick off our highly anticipated landmark asthma stratification project, with our first subject enrolled in August 2016. This dynamic phenotyping project aims to characterise asthma not only in the static or baseline state, but also throughout the evolution of an exacerbation following viral infection. These results will help us characterise asthma patients according to clinical and biomarker phenotypes to differentiate subtypes of asthma patients- enabling the development of targeted therapies, disease biomarkers and predictive tools. An interim analysis is slated for mid-2017, at which time we will examine what differentiators we are picking up, and which will set the course for the remainder of the project. We will be following the pathomics methodology we developed with our flu work, with similar timeframes for output based on completion of the sample collection phase.
Asthma Digital Predictor
In addition, our ability to collect and analyse samples to identify patterns of association offers a compelling opportunity to connect biology and digital data to design powerful disease algorithms, and work is ongoing in this area.
If you are interested to find out more about these and other hVIVO developments and innovations, and how there may be a collaborative or partnering opportunity with your organisation, then please use the “Contact Us” form on this website.